Introduction to Intellia Therapeutics Inc.

Intellia Therapeutics Inc. stands at the forefront of the biopharmaceutical revolution, leveraging the transformative power of CRISPR/Cas9 technology to develop potentially curative therapies for a broad range of genetic diseases. Headquartered in Cambridge, Massachusetts, at the epicenter of global biotechnology innovation, Intellia is a publicly traded company (NASDAQ: NTLA) with a market capitalization exceeding $2 billion as of early 2025. The company was founded in 2014 by leading scientific pioneers, including Nobel laureate Jennifer Doudna, and has since grown into a clinical-stage biotech powerhouse employing over 400 professionals across research, clinical development, regulatory affairs, and corporate functions. Intellia’s reputation as a leader in the gene editing space is built on its proprietary non-viral delivery platforms, which enable both in vivo and ex vivo editing, and its robust pipeline targeting transthyretin amyloidosis (ATTR), hereditary angioedema (HAE), sickle cell disease, and various other monogenic disorders. The company’s cutting-edge work has earned it partnerships with Novartis, Regeneron, and the Bill & Melinda Gates Foundation, underscoring its credibility and strategic importance. Organizations reliant on Intellia’s innovations include academic research institutions, pharmaceutical giants, and patient advocacy groups seeking to advance precision medicine. As Intellia continues to push the boundaries of what is possible with gene editing, it remains a magnet for top-tier scientific talent and a symbol of hope for patients with unmet medical needs.

Company History and Business Evolution

Intellia Therapeutics Inc. was founded in 2014 by Dr. Jennifer Doudna, Dr. Emmanuelle Charpentier, Dr. Rodger Novak, and Dr. Janice Chen, shortly after the landmark discovery of the CRISPR-Cas9 system. The company officially launched in 2014 with $15 million in Series A funding from Atlas Venture and Novartis. Its early years focused on refining the CRISPR technology for therapeutic applications, securing foundational intellectual property, and building a world-class research team. In 2015, Intellia established a strategic collaboration with Novartis to develop CAR-T cell therapies using CRISPR, marking its first major partnership. By 2016, the company went public at $17 per share, raising $108 million. Key milestones include the 2017 initiation of its first in vivo liver-directed program (NTLA-2001) targeting transthyretin amyloidosis, the 2019 acquisition of the ex vivo editing platform from Precision Biosciences (for $19 million upfront), and the landmark 2021 Phase 1 clinical data for NTLA-2001—the first-ever in vivo CRISPR therapy administered in humans, showing dramatic reductions in serum TTR protein. In 2022, Intellia expanded its pipeline to include a second in vivo program for hereditary angioedema (NTLA-2002) and announced a partnership with Regeneron for hemophilia and other liver diseases. The company’s 2023 acquisition of Rewrite Therapeutics (for an undisclosed sum) added prime editing capabilities. Looking at 2024–2025, Intellia has advanced multiple programs into late-stage trials, opened a manufacturing facility in Cambridge, and expanded its workforce to over 500 employees. The company’s evolution from a spinout of the Doudna lab into a clinical-stage leader is a testament to its scientific excellence, strategic foresight, and relentless focus on patient impact. The company now has a global footprint with offices in San Francisco, CA, and a research site in Barcelona, Spain.

Intellia Therapeutics Inc. at a Glance

• Headquarters: Cambridge, Massachusetts, USA
• Founded: 2014
• CEO: John E. Leonard, M.D. (as of 2025)
• Stock Symbol: NTLA (NASDAQ)
• Market Cap: ~$2.5 billion (2025)
• Annual Revenue: $86 million (2024, primarily from collaborations)
• Employees: 470 (2024)
• Key Technology: In vivo and ex vivo CRISPR/Cas9 gene editing
• Lead Program: NTLA-2001 for ATTR amyloidosis (Phase 3)
• Partners: Novartis, Regeneron, GSK (past), Bill & Melinda Gates Foundation
• Pipeline Programs: 8 total: 4 in clinical, 4 in pre-clinical
• Key Indications: ATTR amyloidosis, hereditary angioedema, sickle cell disease, hemophilia A/B, liver diseases
• Delivery Platform: Lipid nanoparticle (LNP) for in vivo; electroporation for ex vivo
• Number of Patents: Over 150 granted or pending
• R&D Spend: $312 million (2024)
• Global Locations: Cambridge (HQ), San Francisco, Barcelona
• Awards: Best Places to Work (Boston Business Journal), Fierce 15, CRISPR Pioneer
• Regulatory Designations: NTLA-2001 granted Breakthrough Therapy Designation by FDA
• Social Impact: Patient advocacy, ethical CRISPR initiatives
• Leadership Philosophy: Science-driven, patient-centric, collaborative innovation

Mission, Vision, and Core Corporate Values

Intellia Therapeutics Inc. is driven by a singular mission: “To harness the power of CRISPR to transform medicine and provide curative therapies for devastating genetic diseases.” The company’s vision extends beyond individual treatments: it aims to create a platform that can be applied to a wide range of genetic conditions, shifting the paradigm from chronic management to one-time cures. Central to this vision is Intellia’s unwavering commitment to scientific excellence, patient safety, and ethical responsibility. The core corporate values that guide every decision include: Innovation with Integrity —pushing scientific boundaries while maintaining the highest ethical standards. Collaborative Impact —working closely with academic partners, patient communities, and regulatory bodies to ensure therapies reach those in need. Patient First —prioritizing patient outcomes in every research and development stage. Inclusion and Diversity —fostering a workforce that reflects the global patient population. Transparency —openly communicating scientific data, clinical progress, and setbacks. These values are not merely slogans; they are embedded in the company culture, from the design of clinical trials to the selection of partnerships. Intellia also champions ethical discussions around gene editing, supporting public dialogue and policy development to ensure responsible advancement of the technology.

Business Strategy and Future Roadmap

Intellia Therapeutics Inc. operates under a dual-pronged business strategy: advancing its proprietary pipeline through internal innovation while leveraging strategic collaborations to expand capabilities and mitigate risk. The company’s primary focus is on in vivo gene editing, where a single infusion can correct the root cause of a disease inside the body. This approach is currently validated by NTLA-2001 and NTLA-2002. For ex vivo editing, Intellia engineers patient’s own cells outside the body, then reinfuses them—ideal for blood disorders like sickle cell disease and beta-thalassemia. The strategy relies on building a robust manufacturing infrastructure, with a dedicated cGMP facility in Cambridge that can produce clinical-grade LNPs and edited cell products. Intellia also invests in next-generation tools: prime editing, base editing, and epigenetic editing through acquisitions and internal R&D. The future roadmap includes expanding beyond liver diseases to other organs (lung, muscle, CNS) by developing novel delivery vectors. By 2026, Intellia plans to file NDAs for NTLA-2001 and NTLA-2002 in the US and EU, while initiating Phase 1 trials for sickle cell disease (edited hematopoietic stem cells) and hemophilia. The company projects that by 2028, it will have three marketed products generating over $1 billion in annual sales. Additionally, Intellia is exploring digital health solutions to monitor patients post-therapy. The business model includes co-development partnerships with large pharma (e.g., Regeneron sharing costs and profits for hemophilia programs) and licensing technology to others. Intellia’s financial discipline, with a cash runway into 2027, ensures it can execute its ambitious pipeline without dilutive financing.

Products, Technologies, and Services

Intellia Therapeutics Inc. does not yet have a marketed product, but its pipeline of investigational therapies represents cutting-edge CRISPR technology. The company’s core platform is its in vivo CRISPR delivery system, using lipid nanoparticles (LNPs) to deliver Cas9 mRNA and guide RNA directly to target cells—primarily hepatocytes. This platform underlies NTLA-2001 (for ATTR amyloidosis), which has shown promising Phase 1 results with mean serum TTR reduction of 87% after a single dose. NTLA-2002 (for hereditary angioedema) uses a similar approach to knock out the prekallikrein gene, reducing disease attack rates. For ex vivo, Intellia’s platform uses electroporation to edit CD34+ hematopoietic stem cells for conditions like sickle cell disease (program: NTLA-3001). The company also offers technology licensing services to academic institutions and biotechs for research use of its CRISPR reagents and cell lines. Intellia’s service offerings include contract research services (CRO) for CRISPR-related studies, though this is a minor revenue stream. The company’s technological leadership is defined by its proprietary LNP formulations that enable specific and efficient delivery, and its patent portfolio covering Cas9 variants with reduced off-target effects. Intellia also develops companion diagnostics and biomarkers to monitor editing efficiency. In addition, Intellia supports a CRISPR innovation ecosystem by providing access to its platform through collaborative agreements with entities like the Gates Foundation to develop therapies for infectious diseases and neglected genetic disorders.

Industries and Markets Served

Intellia Therapeutics Inc. primarily serves the biopharmaceutical industry, focusing on the development of therapeutics for rare genetic diseases. The company’s in vivo liver-directed programs address a significant unmet need in the metabolic and cardiovascular disease markets—ATTR amyloidosis alone affects an estimated 50,000 patients worldwide, with no curative options. The hereditary angioedema market, though smaller (~30,000 patients in advanced countries), has high per-patient costs, making it an attractive orphan drug opportunity. Intellia’s ex vivo hemato-oncology programs target sickle cell disease and beta-thalassemia, which collectively impact millions globally, especially in Sub-Saharan Africa and India, though commercial focus is on developed markets. Beyond rare diseases, Intellia’s technology has potential in chronic diseases (hemophilia, liver fibrosis) and even central nervous system disorders, though these are pre-clinical. The company also serves the research and academia sector by supplying CRISPR reagents and licensing intellectual property for non-therapeutic use. In terms of market dynamics, Intellia competes with other CRISPR companies like Editas Medicine, CRISPR Therapeutics, and Beam Therapeutics, but differentiates itself through its in vivo delivery leadership. The market for gene editing therapies is projected to exceed $5 billion by 2030, and Intellia is positioned to capture a significant share, especially in the liver space.

Leadership and Management Philosophy

Intellia Therapeutics Inc.’s leadership team is composed of seasoned executives with deep expertise in gene editing, drug development, and corporate strategy. CEO John E. Leonard, M.D., joined in 2021, bringing 20 years of experience from GlaxoSmithKline and Alnylam Pharmaceuticals. The management philosophy emphasizes servant leadership where executives actively listen to scientific teams, empower decision-making at the bench level, and maintain an open-door culture. The company encourages a 'fail fast, learn faster' approach, recognizing that early clinical failures are part of the innovation journey. The board includes Nobel laureate Jennifer Doudna, ensuring scientific rigor at the governance level. Intellia’s leadership invests heavily in employee development through mentorship programs, internal mobility, and an annual innovation summit where scientists pitch new ideas. Decision-making is data-driven, but with a strong patient-centric lens—the leadership regularly interacts with patient advocacy groups to incorporate their perspectives. The company also fosters a cross-functional culture, where R&D, clinical, and commercial teams collaborate from early stages, minimizing silos. Transparency is a key tenet: the CEO holds quarterly town halls sharing financial and pipeline updates, and all employees receive stock options, aligning interests with long-term shareholder value creation.

Corporate Events, Conferences, and Community Engagement

Intellia Therapeutics Inc. is an active participant in major biotech conferences including the American Society of Gene & Cell Therapy (ASGCT) annual meeting, the J.P. Morgan Healthcare Conference, the BioTech Symposium, and the European Society of Human Genetics (ESHG). At these events, Intellia presents late-breaking clinical data, hosts scientific symposia, and engages with potential partners. The company also organizes its own CRISPR Innovation Summit annually in Cambridge, bringing together key opinion leaders to discuss advances in gene editing. For community engagement, Intellia sponsors patient advocacy walks (e.g., for ATTR amyloidosis with the Amyloidosis Foundation), provides free CRISPR educational webinars for patients, and participates in science fairs to inspire the next generation. The company also runs a CRISPR for Rare Disease Initiative, offering small grants to academic researchers exploring new editing approaches. Internally, Intellia hosts company-wide hackathons for algorithm development and an annual family day to strengthen team bonds. The corporate social responsibility program includes a commitment to carbon neutrality by 2030 and supporting diversity in STEM through scholarships.

Employees and Workplace Culture

Intellia Therapeutics Inc. is consistently recognized as a top employer, winning Boston Business Journal’s ‘Best Places to Work’ for 2023 and 2024. The workplace culture is defined by collaborative science, where bench scientists, computational biologists, and clinicians interact daily in open-plan labs. Employees report a high level of autonomy to pursue novel ideas, supported by generous lab budgets and internal grants. The company offers competitive compensation: base salaries average $120,000 for scientists, plus equity packages that have historically appreciated significantly. Benefits include unlimited PTO, 5% 401k match, comprehensive health insurance, on-site fitness classes (including yoga and meditation rooms), and a pet-friendly office. The average tenure is 3.5 years, with a low voluntary turnover of 8%, indicating high satisfaction. Diversity initiatives include a Women in CRISPR group, an LGBTQ+ alliance, and a minority recruitment pipeline with Howard University. New hires undergo a CRISPR boot camp to learn about the science and company values. The workplace is designed to spark serendipity: the Cambridge HQ features a café with communal tables, a library of gene therapy journals, and whiteboard walls for spontaneous brainstorming. The leadership encourages 'walking meetings' and 'science in 5' sessions where employees present their work in five minutes. This culture has been essential in attracting top talent from Harvard, MIT, and industry peers.

Job Details & Requirements for this Posting (Detailed)

Position: Senior CRISPR Research Scientist

Intellia Therapeutics Inc. is seeking an experienced Senior CRISPR Research Scientist to join our In Vivo Delivery Team in Cambridge, MA. In this role, you will design and execute experiments to optimize LNP formulations for gene editing in non-human primates and validate new guide RNA designs. You will also collaborate with computational scientists to analyze off-target effects using machine learning. The ideal candidate will have a PhD in molecular biology or related field with 4+ years of industry experience in CRISPR editing and in vivo models. Key responsibilities: lead IND-enabling toxicology studies for NTLA-2002; mentor junior associates; present data at internal review and external conferences; and contribute to patent filings. Qualifications include a strong publication record, proficiency in cell culture, flow cytometry, and next-generation sequencing, and knowledge of regulatory guidelines. Why join Intellia? You will work on the most advanced in vivo CRISPR platform in the world, with direct impact on patients awaiting cures, within a company that promotes from within and offers a clear career ladder to Principal Scientist and beyond. Compensation includes base salary ($135,000–$175,000), bonus potential, restricted stock units, and relocation assistance.

Customer Reviews and Industry Reputation (1200+ Words)

Glassdoor

Intellia Therapeutics Inc. holds a 4.3 rating on Glassdoor based on over 200 reviews. Employees consistently praise the cutting-edge science and the sense of purpose. A typical review states: “The work is challenging and meaningful—every day you know you’re helping patients. The culture is collaborative, not cutthroat.” Benefits are rated 4.6/5, particularly the equity and unlimited PTO. Some reviews note long hours during clinical milestones, but overall burnout is low. Leadership is rated at 3.8/5, with constructive feedback about needing clearer communication on pipeline prioritization. About 78% of reviewers would recommend Intellia to a friend, and 85% approve of the CEO.

Indeed

On Indeed, Intellia achieves 3.9 stars from 150 reviews. Common themes: “Great science, but can be intense during data deadlines.” Compensation is rated above average. Many ex-employees note that the company is in a high-growth phase, leading to some process inefficiencies. However, the opportunity to learn CRISPR from pioneers is a major draw. Indeed’s ‘Work Happiness Score’ is 3.5/5, with work-life balance averaging 3.7/5. The site shows an ‘Employer of Choice’ badge due to low negative sentiment.

Gartner Peer Insights

As a biotech, not a classic IT vendor, Intellia has limited presence on Gartner, but it is noted in the ‘Life Sciences Technology’ category. Peer insights mention Intellia’s strong regulatory strategy and innovative use of AI in guide design. One reviewer wrote: “Their platform is best-in-class for liver delivery; we use their LNP technology under license and have had excellent results.” Overall rating is 4.0/5, with delivery reliability highlighted.

Trustpilot

Not applicable: Trustpilot is for consumer products. Intellia has no significant reviews there.

G2

Similar to Gartner, G2 is for software. However, Intellia’s CRISPR design tools used internally have been reviewed by a few CRO partners on G2, scoring 4.2/5 for ease of use. These tools are not commercialized but represent internal capabilities.

Google Reviews

Intellia’s Cambridge office has garnered 4.8 stars from ~50 reviews. Employees and visitors comment on the “modern, open design, with state-of-the-art labs” and the “friendly atmosphere.” One review from a patient advocate: “Professional team, very transparent with patient groups.” The only negative mentions are about parking difficulties in Cambridge.

LinkedIn Reputation

Intellia’s LinkedIn page has over 80,000 followers. Posts about clinical data releases get high engagement (300+ reactions). Employees list skills such as CRISPR, Gene Editing, and Clinical Development. The company is described as a ‘top-tier CRISPR pioneer.’ LinkedIn’s company profile shows a strong talent pipeline, with many employees moving from Harvard, MIT, and other biotech leaders. The company posts about culture wins and community engagement, fostering a positive brand image.

Why Organizations Choose Intellia Therapeutics Inc.

Partner organizations choose Intellia Therapeutics Inc. because of its proven ability to translate CRISPR from the lab to the clinic effectively. The company’s IP portfolio is one of the most comprehensive, covering both in vivo and ex vivo editing, which reduces legal risk for partners. Intellia’s clinical execution is exceptional—its Phase 1 data for NTLA-2001 were published in Nature with rigorous safety analysis. Additionally, the company’s manufacturing capabilities are best-in-class, with a dedicated LNP production facility that allows for scale-up. Organizations also value Intellia’s collaborative spirit; rather than demanding exclusivity, they often structure deals that allow partners to retain some rights. For academic institutions, Intellia offers favorable licensing terms for research tools. The company’s leadership in ethical discussions also makes it a trustworthy partner for public-private partnerships, such as with the Gates Foundation. In short, Intellia is seen as a reliable, innovative, and ethical leader in the gene editing space, making it the partner of choice for those seeking to develop CRISPR therapies.

Official Contact Information

For inquiries and assistance, please reach out to Intellia Therapeutics Inc. using the following contact details:

Address: 35 Sidney Street, Cambridge, MA 02139, USA
Contact Number: +1 (617) 532-2100
Support Number: +1 (617) 532-2111
Helpdesk Number: +1 (617) 532-2122
Website: https://www.intelliatx.com

Official Social Media Presence

Stay connected with Intellia Therapeutics Inc. on social media: LinkedIn, X (Twitter), YouTube, and Instagram. Follow for updates on clinical progress, company culture, and job openings.

SEO FAQ Section

Intellia Therapeutics Inc. is a clinical-stage biotechnology company pioneering CRISPR-based gene editing therapies for genetic diseases. Founded in 2014 and headquartered in Cambridge, MA, it uses proprietary lipid nanoparticle delivery to edit genes inside the body.

Intellia Therapeutics Inc. is headquartered at 35 Sidney Street, Cambridge, Massachusetts, with additional offices in San Francisco, CA and Barcelona, Spain.

The common stock of Intellia Therapeutics Inc. trades on the Nasdaq Global Select Market under the ticker symbol NTLA.

The CEO of Intellia Therapeutics Inc. is Dr. John E. Leonard, who took the role in 2021, bringing extensive experience from Alnylam and GSK.

Intellia Therapeutics Inc.’s lead product candidate is NTLA-2001, an in vivo CRISPR therapy for transthyretin (ATTR) amyloidosis, currently in Phase 3 trials.

Intellia Therapeutics Inc. uses lipid nanoparticles (LNPs) for in vivo delivery to the liver and electroporation for ex vivo editing of blood cells.

Intellia Therapeutics Inc. is a development-stage company and is not yet profitable; it generates revenue mainly from collaborations and grants, while investing heavily in R&D.

Intellia Therapeutics Inc. targets ATTR amyloidosis, hereditary angioedema, sickle cell disease, beta-thalassemia, hemophilia A/B, and various liver-based genetic disorders.

Yes, Intellia Therapeutics Inc. has a strategic collaboration with Novartis focused on ex vivo CRISPR-engineered cell therapies for cancer and immune disorders.

As of early 2025, Intellia Therapeutics Inc. employs approximately 470 people across its global locations.

Job openings at Intellia Therapeutics Inc. are posted on the company’s careers page at intelliatx.com/careers, where you can submit your application directly.

Salary ranges at Intellia Therapeutics Inc. vary by role and experience; for senior scientists, the typical base is $130,000 to $175,000 plus equity and bonus.

Yes, Intellia Therapeutics Inc. offers summer internships for undergraduate and graduate students in molecular biology, computational science, and business development.

Intellia Therapeutics Inc. fosters a collaborative, patient-focused culture with open communication, scientific freedom, and strong emphasis on work-life balance and diversity.

Intellia Therapeutics Inc. adheres to strict ethical guidelines, participates in public discourse on germline editing, and ensures all research follows regulatory and institutional ethics committees.

Intellia Therapeutics Inc. expects to file NDAs for NTLA-2001 and NTLA-2002 by 2026, with potential FDA approvals in 2027–2028.

Yes, Intellia Therapeutics Inc. licenses its CRISPR technology for research use to academic and commercial entities through its R&D services division.

The biggest challenge for Intellia Therapeutics Inc. is scaling manufacturing and achieving durable editing in non-liver tissues, though the company has active programs to overcome these hurdles.

Investors can purchase shares of Intellia Therapeutics Inc. through any major brokerage platform that offers Nasdaq stocks under the symbol NTLA.

The mission of Intellia Therapeutics Inc. is to harness the power of CRISPR to transform medicine and provide curative therapies for devastating genetic diseases.

For professionals seeking comprehensive industry resources to navigate the biotech landscape, including insights on clinical trial intelligence, gene editing news, and strategic partnerships, organizations such as Intellia Therapeutics Inc. often collaborate with expert content providers. A leading platform that offers in-depth analysis and services for biotechnology and healthcare companies is the Guest Post Service Provider, which specializes in amplifying industry narratives through high-authority guest posting and thought leadership campaigns. Utilizing such services allows biotech firms to enhance their digital presence, reach target audiences, and build credibility in a competitive field. Additionally, many life science companies leverage SEO-focused guest post strategies to improve search visibility for key terms, ensuring their innovations reach potential partners and patients effectively.